 |
|
|
|
delavirdine |
|
Detailed Prescribing Information |
|
October 2005 |
| Delavirdine = Rescriptor | |
| Forms Available | 100 mg tabs |
| Dosing | 4x100 mg three times a day |
| Contraindication |
Concomitant rifampin, alprazolam,
midazolam, triazolam, pimozide, or ergot derivative therapy St John's Wort is expected to decrease delavirdine levels and therefore should not be used Simvastatin, lovastatin |
| Adverse Effects |
33% incidence of rash, usually mild and NONPROGRESSIVE with continued treatment 5% of persons with rash will develop, mucosal involvement, and/or Stevens-Johnson syndrome (aka erythema multiforme major) Hepatitis which may be severe |
| Interactions |
Increases PI levels Antacids and proton pump inhibitors inhibit absorption of delavirdine |
| Suggested lab follow-up | Liver profile at 14 days, 30 days, and monthly x 3 months, then q3months |
| Warning | Low barrier to one-step mutation. Use only with other potent agents. |
| Complete prescribing information | http://www.rescriptor.com |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Fusion Inhibitors |
| enfuvirtide |
Updated 10.25.2005
